Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort
Ross McQueenie(University of Glasgow), Barbara I. Nicholl(University of Glasgow), Jana Anderson(Johnson & Johnson (United Kingdom)), Frances S Mair(University of Glasgow), Patrick B. Mark(University of Glasgow), Jill P. Pell(University of Glasgow), Claire E. Hastie(University of Glasgow), Catherine O’Donnell(University of Glasgow), Bhautesh Jani(University of Glasgow), Naveed Sattar(University of Glasgow), Michael Sullivan(University of Glasgow), Claire L. Niedzwiedz(University of Glasgow), Hamish Foster(University of Glasgow), Frederick K. Ho(University of Glasgow), Srinivasa Vittal Katikireddi(MRC/CSO Social and Public Health Sciences Unit)
Cited by 151
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
|The Lancet Diabetes & Endocrinology|2019|1.6k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k
Multimorbidity
|Nature Reviews Disease Primers|2022|1.3k